DBVT — DBV Technologies S.A.

Is DBVT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

DBV Technologies S.A. (DBVT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.99. The rating moved from Neutral to Strong Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

DBV Technologies is a clinical-stage company with a differentiated epicutaneous immunotherapy approach that targets a large unmet need in food allergy. Upside is primarily tied to positive clinical readouts, regulatory approvals, and potential partnerships or acquisition interest that would improve commercialization prospects and payer access. Near-term valuation is constrained by typical biotech execution risk: binary trial outcomes, limited cash runway, and competitive alternatives. Given these dynamics, the stock may trade near-term around current levels with elevated volatility; favorable clinical/regulatory news or a strategic partnership could provide material upside, while clinical setbacks, funding needs, or reimbursement challenges could trigger sharp downside.

Key factors

  • Clinical-stage biopharma with a novel epicutaneous immunotherapy platform addressing food allergies; platform differentiation vs oral/biologic approaches could command premium if efficacy/safety are demonstrated
  • Large addressable market for peanut and other food allergy treatments, with meaningful commercial upside if regulatory approval and payer acceptance are achieved
  • Historical clinical and regulatory volatility typical of allergy immunotherapy programs increases binary outcome sensitivity to trial readouts and agency interactions
  • Balance sheet and cash runway uncertainty for small-cap biotech absent a partnering/licensing deal or financing round — capital needs could dilute existing shareholders or pressure share price
  • Partnering or M&A interest from larger pharma would materially de‑risk commercial execution and reimbursement access but is uncertain and timing-dependent
  • Current broader market tone is risk-on but muted; defensive flows into large-cap pharma reduce immediate appetite for small, high-volatility biotech stories
  • No meaningful social or EDGAR signals available to confirm market sentiment or recent material filings

Risks

  • Clinical failure or equivocal efficacy/safety readouts in ongoing or future trials, leading to regulatory setbacks
  • Regulatory rejection, labeling restrictions, or onerous post-approval requirements that limit commercial potential
  • Insufficient cash runway forcing dilutive equity raises or unfavorable licensing terms
  • Competitive pressure from approved therapies (e.g., oral immunotherapy products) and new entrants including biologics or other modality innovators
  • Payer resistance to reimbursement or narrow coverage limiting uptake even if approved
  • Market volatility for small-cap biotech amplifying downside on negative news or liquidity squeezes
  • Potential manufacturing or commercialization scaling challenges for a novel delivery platform

See today's live rating, score and targets

Members see the live hourly rating for DBVT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.